Cutaneous T-Cell Lymphoma (CTCL) Withdrawn Phase 0 Trials for Durvalumab (DB11714)

Also known as: Lymphoma, Cutaneous T-Cell / Cutaneous T-Cell Lymphomas / Cutaneous T-Cell Lymphoma / Cutaneous lymphoma / Lymphoma, T-Cell, Cutaneous

IndicationStatusPhase
DBCOND0071861 (Cutaneous T-Cell Lymphoma (CTCL))Withdrawn0
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03235869Radiation Therapy Plus Durvalumab for Tumor-Stage Cutaneous T-Cell LymphomaTreatment